DE60035779D1 - Alpha v integrin-rezeptor antagonisten - Google Patents

Alpha v integrin-rezeptor antagonisten

Info

Publication number
DE60035779D1
DE60035779D1 DE60035779T DE60035779T DE60035779D1 DE 60035779 D1 DE60035779 D1 DE 60035779D1 DE 60035779 T DE60035779 T DE 60035779T DE 60035779 T DE60035779 T DE 60035779T DE 60035779 D1 DE60035779 D1 DE 60035779D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
integrin receptor
alpha
present
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60035779T
Other languages
English (en)
Other versions
DE60035779T2 (de
Inventor
Paul J Coleman
Mark E Duggan
Wasyl Halczenko
George D Hartman
John H Hutchinson
Robert S Meissner
Michael A Patane
James J Perkins
Jiabing Wang
Michael J Breslin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE60035779D1 publication Critical patent/DE60035779D1/de
Publication of DE60035779T2 publication Critical patent/DE60035779T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60035779T 1999-06-02 2000-05-30 Alpha v integrin-rezeptor antagonisten Expired - Fee Related DE60035779T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13710199P 1999-06-02 1999-06-02
US137101P 1999-06-02
US17921600P 2000-01-31 2000-01-31
PCT/US2000/014901 WO2000072801A2 (en) 1999-06-02 2000-05-30 Alpha v integrin receptor antagonists
US179216P 2009-05-18

Publications (2)

Publication Number Publication Date
DE60035779D1 true DE60035779D1 (de) 2007-09-13
DE60035779T2 DE60035779T2 (de) 2008-04-30

Family

ID=26834930

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035779T Expired - Fee Related DE60035779T2 (de) 1999-06-02 2000-05-30 Alpha v integrin-rezeptor antagonisten

Country Status (28)

Country Link
US (1) US6410526B1 (de)
EP (1) EP1187592B1 (de)
JP (3) JP3808707B2 (de)
KR (1) KR20020021380A (de)
CN (1) CN1589145A (de)
AT (1) ATE368462T1 (de)
AU (1) AU749351B2 (de)
BG (1) BG106232A (de)
BR (1) BR0011108A (de)
CA (1) CA2373937A1 (de)
CY (1) CY1107746T1 (de)
CZ (1) CZ20014308A3 (de)
DE (1) DE60035779T2 (de)
DK (1) DK1187592T3 (de)
DZ (1) DZ3263A1 (de)
EA (1) EA200101272A1 (de)
EE (1) EE200100642A (de)
ES (1) ES2288861T3 (de)
HR (1) HRP20010895A2 (de)
HU (1) HUP0302468A2 (de)
IL (1) IL146378A0 (de)
IS (1) IS6157A (de)
NO (1) NO323906B1 (de)
PL (1) PL353364A1 (de)
PT (1) PT1187592E (de)
SK (1) SK17442001A3 (de)
TR (1) TR200103431T2 (de)
WO (1) WO2000072801A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EP1254116A4 (de) 2000-01-24 2003-04-23 Merck & Co Inc Alpha v integrin-rezeptor antagonisten
AU2001269876A1 (en) 2000-06-15 2001-12-24 Mark Laurence Boys Heteroarylalkanoic acids as integrin receptor antagonists
WO2002007730A1 (en) * 2000-07-26 2002-01-31 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2002022616A2 (en) * 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
AU2001296439A1 (en) * 2000-10-04 2002-04-15 Merck & Co., Inc. Phosphoric acid salt of an integrin receptor antagonist
WO2002053099A2 (en) * 2001-01-03 2002-07-11 Merck & Co., Inc. Methods and compositions for treating periodontal disease
RU2316337C2 (ru) 2001-04-24 2008-02-10 Мерк Патент Гмбх КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
MXPA05006587A (es) 2002-12-20 2005-12-14 Pharmacia Corp Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
WO2004078109A2 (en) * 2003-03-07 2004-09-16 Merck Sharp & Dohme Limited PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ανβ3 RECEPTOR ANTAGONISTS
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP2338518A1 (de) 2006-01-18 2011-06-29 Merck Patent GmbH Spezifische Krebsbehandlung mit Integrin-Liganden
BRPI0806596A2 (pt) 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
US9345739B2 (en) 2007-11-08 2016-05-24 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
MX2011012491A (es) 2009-05-25 2011-12-14 Merck Patent Gmbh Administracion continua de cilengitida en tratamientos contra el cancer.
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
RU2698195C2 (ru) 2013-02-07 2019-08-23 Сайфлуор Лайф Сайенсиз, Инк Фторсодержащие антагонисты интегрина
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
RS62591B1 (sr) 2013-09-24 2021-12-31 Fujifilm Corp Novo jedinjenje koje sadrži azot ili njegova so ili njihov kompleks sa metalom
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
EP3259271B1 (de) * 2015-02-19 2021-05-05 SciFluor Life Sciences, Inc. Fluorierte derivate von 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propansäure und verwendungen davon
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2017189828A1 (en) * 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
MX2019000043A (es) * 2016-07-05 2019-07-04 Univ Rockefeller Antagonistas de integrina de tetrahidronaftiridinpentanamida.
EP3509590A4 (de) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-acyl-aminosäure-verbindungen und verfahren zur verwendung
MA46744A (fr) * 2016-11-08 2019-09-18 Bristol Myers Squibb Co Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v
ES2898835T3 (es) * 2016-11-08 2022-03-09 Bristol Myers Squibb Co Azol amidas y aminas como inhibidores de la integrina alfav
EP4147698A1 (de) 2017-02-28 2023-03-15 Morphic Therapeutic, Inc. Inhibitoren von (alpha-v) (beta-6)-integrin
MX2019010267A (es) 2017-02-28 2020-02-05 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
BR112021003859A2 (pt) 2018-08-29 2021-05-18 Morphic Therapeutic, Inc. inibindo integrina avss6

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843798A (en) 1973-03-12 1974-10-22 Stanley Drug Products Inc Methods and compositions for inducing resistance to bacterial infections
US5025025A (en) 1989-06-28 1991-06-18 Ciba-Geigy Corporation (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity
WO1992019595A1 (en) 1991-05-07 1992-11-12 Merck & Co., Inc. Fibrinogen receptor antagonists
AU3141693A (en) 1991-11-22 1993-06-15 Friedman, Mark M. Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
AU713676B2 (en) 1996-01-16 1999-12-09 Merck & Co., Inc. Integrin receptor antagonists
PT796855E (pt) 1996-03-20 2002-07-31 Hoechst Ag Inibicao da reabsorcao nos ossos e antagonistas de vitronectina
DE69716900T2 (de) 1996-04-10 2003-07-03 Merck & Co., Inc. Alpha v Beta 3 ANTAGONISTEN
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
WO1998008840A1 (en) 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
AU717283B2 (en) 1996-10-30 2000-03-23 Merck & Co., Inc. Integrin antagonists
ES2194223T3 (es) * 1996-10-30 2003-11-16 Merck & Co Inc Antagonistas de la integrina.
WO1998031359A1 (en) 1997-01-17 1998-07-23 Merck & Co., Inc. Integrin antagonists
EP1044001B1 (de) 1997-12-17 2005-07-06 Merck & Co., Inc. Integrinrezeptor antagonisten
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EP1047425A4 (de) 1997-12-17 2009-04-22 Merck & Co Inc Integrinrezeptor antagonisten
NZ504893A (en) * 1997-12-17 2002-10-25 Merck & Co Inc 5, 6, 7, 8-Tetrahydro-[1,8]-naphthyridin-2-yl derivatives useful as integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
IL136314A0 (en) 1997-12-17 2001-05-20 Merck & Co Inc Integrin receptor antagonists

Also Published As

Publication number Publication date
CZ20014308A3 (cs) 2002-03-13
PT1187592E (pt) 2007-10-19
IS6157A (is) 2001-11-13
WO2000072801A2 (en) 2000-12-07
PL353364A1 (en) 2003-11-17
BG106232A (en) 2002-06-28
HRP20010895A2 (en) 2003-08-31
NO20015858D0 (no) 2001-11-30
JP2006206604A (ja) 2006-08-10
CA2373937A1 (en) 2000-12-07
EA200101272A1 (ru) 2002-06-27
JP2006232844A (ja) 2006-09-07
EP1187592A2 (de) 2002-03-20
DE60035779T2 (de) 2008-04-30
JP3808707B2 (ja) 2006-08-16
EP1187592A4 (de) 2002-11-06
BR0011108A (pt) 2002-03-19
NO323906B1 (no) 2007-07-16
ES2288861T3 (es) 2008-02-01
IL146378A0 (en) 2002-07-25
NO20015858L (no) 2002-02-04
AU5724600A (en) 2000-12-18
TR200103431T2 (tr) 2002-06-21
JP2004500326A (ja) 2004-01-08
DZ3263A1 (fr) 2000-12-07
CN1589145A (zh) 2005-03-02
HUP0302468A2 (hu) 2003-11-28
KR20020021380A (ko) 2002-03-20
SK17442001A3 (sk) 2002-03-05
CY1107746T1 (el) 2013-04-18
DK1187592T3 (da) 2007-11-05
ATE368462T1 (de) 2007-08-15
US6410526B1 (en) 2002-06-25
EP1187592B1 (de) 2007-08-01
EE200100642A (et) 2003-02-17
AU749351B2 (en) 2002-06-27
WO2000072801A3 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
DE60035779D1 (de) Alpha v integrin-rezeptor antagonisten
DE69829996D1 (de) Integrin-rezeptor-antagonisten
ATE298338T1 (de) Integrin-rezeptor-antagonisten
DE69720771T2 (de) Integrin antagonist
DE69830806D1 (de) Integrinrezeptor antagonisten
ES2185009T3 (es) Antagonistas de alfa y beta 3'.
DE60126496D1 (de) Alpha v integrin-rezeptor-antagonisten
WO2002090325A3 (en) Benzazepinone alpha v integrin receptor antagonists
ATE320258T1 (de) Dibenzoxazepin-alpha-v-integrin- rezeptorantagonist
YU38300A (sh) Antagonisti integrinskog receptora
YU38200A (sh) Antagonisti integrinskog receptora

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., RAHWAY, N.J., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee